DNA-repair defects and olaparib in metastatic prostate cancer

New England Journal of Medicine

Volumn 373, Issue 18, 2015, Pages 1697-1708

  Mateo, J ^a,b   Carreira, S ^a   Sandhu, S ^a,b   Miranda, S ^a   Mossop, H ^a   Perez Lopez, R ^a,b   Nava Rodrigues, D ^a   Robinson, D ^a,i   Omlin, A ^a,b   Tunariu, N ^a,b   Boysen, G ^a   Porta, N ^a   Flohr, P ^a   Gillman, A ^a   Figueiredo, I ^a   Paulding, C ^a   Seed, G ^a   Jain, S ^d   Ralph, C ^a   Protheroe, A ^e   Hussain, S ^f   Jones, R ^g   Elliott, T ^h   McGovern, U ^c   Bianchini, D ^a,b   Goodall, J ^a   Zafeiriou, Z ^a,b   Williamson, C T ^a   Ferraldeschi, R ^a,b   Riisnaes, R ^a   Ebbs, B ^a   Fowler, G ^a   Roda, D ^a,b   Yuan, W ^a   Wu, Y M ⁱ   Cao, X ⁱ   Brough, R ^a   Pemberton, H ^a   A'Hern, R ^a   Swain, A ^a   Kunju, L P ⁱ   Eeles, R ^a,b   Attard, G ^a,b   Lord, C J ^a   Ashworth, A ^a   Rubin, M A ^j   Knudsen, K E ^k   Feng, F Y ⁱ   Chinnaiyan, A M ⁱ   Hall, E ^a   De Bono, J S ^a,b   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATM PROTEIN, HUMAN; ENZYME INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ATM GENE; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; CHEK2 GENE; CLINICAL ARTICLE; DISORDERS OF DNA SYNTHESIS AND REPAIR; DRUG DOSE REDUCTION; ENZYME INHIBITION; EXOME; FATIGUE; FOLLOW UP; GENE; GENE DELETION; GENE LOSS; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; METASTASIS POTENTIAL; NEUTROPENIA; NEXT GENERATION SEQUENCING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DNA REPAIR; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NEOPLASM METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FATIGUE; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS;

EID: 84946019429     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506859     Document Type: Article

References (41)

1. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79.
2. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-77.
3. Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
4. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010; 467: 543-9.
5. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63: 920-6.
6. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
7. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
8. Fong PCP, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
9. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-50.
10. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-92.
11. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-61.
12. Sandhu SK, Omlin A, Hylands L, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24: 1416-8.
13. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14: 882-92.
14. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-57.
15. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
17. Robinson D, Van Allen EM, Wu Y-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-28.
18. Ong M, Carreira S, Goodall J, et al. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 2014; 111: 828-36.
19. Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6: 254ra125.
20. Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: 1348-55.
21. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
22. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588-99.
23. Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 2014; 33: 3894-907.
24. Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 2015; 67: 795-802.
25. Turenne GA, Paul P, Laflair L, Price BD. Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53. Oncogene 2001; 20: 5100-10.
26. Beamish H, Kedar P, Kaneko H, et al. Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia mutated protein, ATM. J Biol Chem 2002; 277: 30515-23.
27. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281: 1677-9.
28. Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17: 1144-51.
29. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther 2013; 12: 2078-87.
30. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 2007; 104: 19482-7.
31. Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration resistant prostate cancer: COU-AA-302 results. J Clin Oncol 2015; 33: 1356-63.
32. Kote-Jarai Z, Leongamornlert D, Saunders E, et al.. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-4.
33. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.
34. Chenevix-Trench G, Spurdle AB, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002; 94: 205-15.
35. Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol Cell Biol 1997; 17: 2020-9.
36. Barlow C, Eckhaus MA, Schoffer AA, Wynshaw-Boris A. Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice. Nat Genet 1999; 21: 359-60.
37. Buisson R, Dion-Coti A-M, Coulombe Y, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 2010; 17: 1247-54.
38. Chao OS, Goodman OB Jr. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. Mol Cancer Res 2014; 12: 1755-66.
39. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castraterefractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.
40. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum free interval. J Clin Oncol 2010; 28: 2512-9.
41. Ceccaldi R, O'Connor KW, Mouw KW, et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015; 75: 628-34.